QT Imaging Holdings, Inc. (QTI) - 10-Q Summary
Business Context and Reporting Period
Period: Quarterly report for the period ended September 30, 2024 (Q3 2024).
Company Overview: QT Imaging is a medical device company developing body imaging systems using low-frequency sound waves. Its primary product is the QT Breast Scanner. The company completed a business combination with GigCapital5 on March 4, 2024, and is classified as an Emerging Growth Company and Smaller Reporting Company.
Key Developments: The company entered into a Distribution Agreement with NXC Imaging (a subsidiary of Canon Medical Systems) in June 2024, appointing NXC as the exclusive reseller in the U.S. A "Trigger Event" occurred on September 11, 2024, under the Yorkville Note debt agreement due to stock price performance, resulting in mandatory principal repayments and subsequent amendments to the debt terms.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $955,970 | $24,657 | $4,032,168 | $35,404 |
| Gross Profit | $605,303 | $858 | $2,239,934 | $(38,093) |
| Gross Margin | 63.3% | 3.5% | 55.6% | -107.6% |
| Net Loss | $(3,619,494) | $(1,375,939) | $(9,166,958) | $(4,588,900) |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.14) | $(0.77) | $(0.48) |
| Cash and Restricted Cash (End of Period) | $1,564,169 | $54,490 | $1,564,169 | $54,490 |
| Operating Cash Flow (YTD) | $(8,806,402) | $(1,965,772) | $(8,806,402) | $(1,965,772) |
| Total Debt (Current + Long-Term) | $4,356,232 | $4,904,342 | $4,356,232 | $4,904,342 |
| Related Party Notes Payable | $5,408,725 | $3,848,725 | $5,408,725 | $3,848,725 |
Note: Debt figures include current maturities of long-term debt and long-term debt. Related party notes are listed separately in liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly in Q3 2024 ($956k vs $25k) and YTD 2024 ($4.03M vs $35k) driven by the sale of QT Breast Scanners. In Q3 2024, two scanners were sold; in the first nine months of 2024, nine scanners were sold compared to none in the prior year periods.
- Operating Expenses: Total operating expenses rose to $2.93M in Q3 2024 from $1.24M in Q3 2023. This increase is attributed to higher employee compensation, professional services, and insurance costs. YTD SG&A expenses were heavily impacted by $3.94M in non-recurring transaction expenses related to the business combination.
- Interest Expense: Net interest expense surged to $1.46M in Q3 2024 from $133k in Q3 2023, primarily due to the amortization of debt discounts on the Yorkville Pre-Paid Advance and Cable Car Loan.
- Balance Sheet: Cash increased from $165k at year-end 2023 to $1.54M at Q3 2024, funded by financing activities including the Yorkville Note and merger proceeds. Inventory decreased by $1.24M as units were sold.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Capital Resources: Management believes cash on hand, combined with the Standby Equity Purchase Agreement (SEPA) with Yorkville and a recently executed PIPE transaction ($2.56M), will fund operations for at least the next 12 months. However, the company has an accumulated deficit of $32.1M and expects to continue incurring losses.
- Debt Covenants and Trigger Events: A "Trigger Event" occurred on September 11, 2024, when the stock price fell below the Floor Price ($0.8768) for five consecutive days. This triggered mandatory monthly principal payments on the Yorkville Note. The company subsequently amended the note (Omnibus Amendment and Second Amendment) to extend maturity dates and adjust payment schedules, reducing the Floor Price to $0.50.
- Unusual Items:
- Deemed Dividend: A $5.19M deemed dividend was recorded in YTD 2024 due to the modification of equity-classified warrants (reduction of exercise price from $11.50 to $2.30).
- Fair Value Adjustments: Significant non-cash gains were recorded from changes in the fair value of derivative liabilities ($4.8M gain YTD) and warrant liabilities ($200k gain YTD), offset by a $700k loss on earnout liability.
- Risks: Key risks include the ability to raise additional capital, dependence on a single major customer (NXC Imaging accounted for 96% of revenue in Q3 2024), and the need to achieve FDA clearances for new indications to trigger earnout share issuances.
Investor Verification Checklist
- Debt Service Capability: Verify the company's ability to meet the mandatory $500,000 monthly principal payments on the Yorkville Note starting in early 2025, given the current cash burn rate.
- Customer Concentration: Assess the risk associated with NXC Imaging representing 96% of Q3 revenue and the terms of the exclusive distribution agreement.
- PIPE Closing: Confirm the closing of the $2.56M PIPE transaction with related parties scheduled for November 29, 2024, and the cancellation of the $1.56M Extension Note.
- Earnout Milestones: Monitor progress toward the 2024 earnout triggers (FDA clearance for breast cancer screening and revenue/placement targets) which could result in the issuance of up to 3 million shares.
- Stock Price Volatility: Monitor the stock price relative to the $0.50 Floor Price to avoid further Trigger Events under the Yorkville Note.